BHLHE41 suppresses MCF-7 cell invasion via MAPK/JNK pathway.
Anthracenes
/ pharmacology
Basic Helix-Loop-Helix Transcription Factors
/ antagonists & inhibitors
Breast Neoplasms
/ genetics
Cell Line, Tumor
Cell Proliferation
/ genetics
Female
Gene Expression Regulation, Neoplastic
Gene Silencing
Humans
MAP Kinase Kinase 4
/ antagonists & inhibitors
MCF-7 Cells
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Neoplasm Invasiveness
/ genetics
Neoplasm Proteins
/ genetics
Signal Transduction
/ drug effects
Transcriptional Activation
/ genetics
BHLHE41
JNK signalling pathway
breast cancer
invasion
tight junction
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
02
10
2019
revised:
16
11
2019
accepted:
17
12
2019
pubmed:
20
2
2020
medline:
4
5
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
Deregulation of the basic helix-loop-helix family member e41 (BHLHE41) has been characterized as a marker of progression of several cancers. In this study, we aimed to explore the mechanism by which BHLHE41 regulates the invasion of breast cancer cells. BHLHE41 suppresses, whereas the silencing of BHLHE41 promotes tumour invasion of both MCF-7 and MDA-MB-231 cells. Meanwhile, BHLHE41 down-regulated the transcription and translation of SNAI1, SNAI2, VIM and CDH2, and up-regulated those of CLDN1, CLDN4 and CDH1. Reporter assay indicated that silencing of BHLHE41 dramatically activated the MAPK/JNK signalling pathway in MCF-7 cell line and the hypoxia signalling pathway in MDA-MB-231 cell line. Furthermore, silencing of BHLHE41 activated the MAPK/JNK signalling pathway by up-regulating phosphorylated JNK and failed to affect the expression of HIF-1 alpha in MCF-7 cells. After blocking the MAPK/JNK signalling pathway by specific inhibitor SP600125, silencing of BHLHE41 failed to promote tumour cell invasion. These results suggest that BHLHE41 facilitates MCF-7 cell invasion mainly via the activation of MAPK/JNK signalling pathway. In conclusion, although BHLHE41 suppresses tumour invasion in MCF-7 and MDA-MB-231 cell lines, the specific regulatory mechanisms may be different.
Identifiants
pubmed: 32073238
doi: 10.1111/jcmm.15033
pmc: PMC7171311
doi:
Substances chimiques
Anthracenes
0
BHLHE41 protein, human
0
Basic Helix-Loop-Helix Transcription Factors
0
Neoplasm Proteins
0
pyrazolanthrone
1TW30Y2766
MAP Kinase Kinase 4
EC 2.7.12.2
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Banques de données
GENBANK
['NM_030762', 'NM_021101', 'NM_001305', 'NM_005985', 'NM_003068', 'NM_001792', 'NM_003380', 'NM_004360']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4001-4010Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Oncogene. 2008 Jun 12;27(26):3761-4
pubmed: 18223678
Mol Cell Biol. 2015 Dec;35(24):4096-109
pubmed: 26391953
Cell Commun Signal. 2017 Jun 12;15(1):21
pubmed: 28606091
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3434-3439
pubmed: 29531056
J Exp Clin Cancer Res. 2016 Apr 19;35:69
pubmed: 27095063
Int J Mol Med. 2013 Apr;31(4):855-60
pubmed: 23426649
J Cell Mol Med. 2020 Apr;24(7):4001-4010
pubmed: 32073238
Leukemia. 2014 Jul;28(7):1564-8
pubmed: 24561520
Science. 2009 Aug 14;325(5942):866-70
pubmed: 19679812
J Pathol. 2011 Jul;224(3):420-9
pubmed: 21506129
Nat Commun. 2016 Jul 07;7:12098
pubmed: 27384883
Histochem Cell Biol. 2019 May;151(5):369-384
pubmed: 30284609
J Biol Chem. 2003 May 9;278(19):16899-907
pubmed: 12624110
Genes Cells. 2010 Apr 1;15(4):315-25
pubmed: 20236182
J Cell Physiol. 2017 Aug;232(8):2210-2220
pubmed: 27966776
Nature. 2002 Oct 24;419(6909):841-4
pubmed: 12397359
Nature. 2012 Jul 19;487(7407):380-4
pubmed: 22801492
Am J Pathol. 2019 Apr;189(4):773-783
pubmed: 30664860
Curr Opin Neurobiol. 2013 Oct;23(5):873-9
pubmed: 23702243
Nat Immunol. 2017 Apr;18(4):442-455
pubmed: 28250425
Toxins (Basel). 2017 Apr 13;9(4):
pubmed: 28406452
BMC Cancer. 2014 Jul 05;14:487
pubmed: 24997474
Mol Carcinog. 2018 Sep;57(9):1116-1129
pubmed: 29704436
Mol Med Rep. 2016 Jun;13(6):5365-71
pubmed: 27121679
PLoS Genet. 2017 Jul 17;13(7):e1006872
pubmed: 28715484
Biomed Pharmacother. 2018 Sep;105:582-589
pubmed: 29890466
Int J Mol Med. 2015 Mar;35(3):815-20
pubmed: 25524285
Mol Med Rep. 2018 Oct;18(4):3859-3865
pubmed: 30106153
Oncol Rep. 2019 Apr;41(4):2137-2147
pubmed: 30816499
Mol Med Rep. 2017 Jul;16(1):43-48
pubmed: 28498447
Mol Cell Biochem. 2019 Jan;450(1-2):167-174
pubmed: 29926321
EMBO J. 2002 Oct 15;21(20):5417-26
pubmed: 12374742
Int J Oncol. 2012 Oct;41(4):1337-46
pubmed: 22825629
Am J Cancer Res. 2016 Aug 01;6(8):1741-57
pubmed: 27648362
J Cancer. 2016 Jan 01;7(2):153-9
pubmed: 26819638